Exhibiting at FOOD INGREDIENTS CHINA 2025

CABIO Biotech (Wuhan) Co., Ltd.（嘉必优生物技术（武汉）股份有限公司）is a pioneering biotechnology enterprise specializing in the R&D, production, and sales of high-value nutritional ingredients through microbial fermentation technology. Founded in 2004 and headquartered in Wuhan, China, CABIO has established itself as a global leader in the field of human nutrition, animal nutrition, and personal care ingredients, with a strong presence across international markets.

Core Business

CABIO’s core business lies in microbial fermentation-based manufacturing of essential nutritional lipids and functional ingredients. The company provides high-purity, high-stability solutions for sectors such as infant formula, dietary supplements, pharmaceuticals, and cosmetics. Its production capabilities include precision fermentation and downstream purification processes, supported by proprietary microbial strains and advanced bioprocessing technologies.

Product and Service Offerings

CABIO’s diversified product portfolio includes:

Human Nutrition:

• Arachidonic Acid (ARA)
• Docosahexaenoic Acid (DHA)
• Beta-Carotene (BC)
• N-Acetylneuraminic Acid (SA) (Sialic Acid)

These products are extensively used in infant nutrition, functional foods, and health supplements.

Animal Nutrition:

• Feed-grade fatty acid oils such as ARA and DHA for improving immunity and growth performance in livestock and aquaculture.

Personal Care:

• Functional bio-based ingredients tailored for cosmetic formulations, with a focus on skin and hair health enhancement.

Specialization and Core USP

CABIO is recognized for its microbial fermentation-based production, ensuring non-GMO, sustainable, and high-purity nutritional ingredients. Its patented strains and fermentation techniques offer a competitive edge in scalability, yield, and cost-efficiency. The company also focuses heavily on infant-grade quality standards, maintaining stringent quality control through GMP, ISO, and HACCP certified facilities.

Financial Performance

CABIO Biotech is listed on the Shanghai Stock Exchange STAR Market (Ticker: 688089). As per its 2022 annual report, the company reported:

• Revenue: RMB 644 million (~USD 94 million)
• Net Profit: RMB 82 million (~USD 12 million)
• R&D Investment: Over 9% of annual revenue

The company has shown consistent year-over-year growth driven by expansion in both domestic and international markets, particularly in the infant formula and dietary supplement segments.

Shipment and Export Data

According to international trade databases including Volza and ImportYeti, CABIO has recorded:

• Over 350 international shipments between 2019 and 2023.
• Primary export destinations: United States, Germany, Australia, South Korea, and the Netherlands.
• Key export products include ARA oil, DHA oil, and Sialic Acid, primarily for infant nutrition manufacturers and dietary supplement brands.

Target Market

CABIO targets:

• Infant formula producers
• Nutraceutical companies
• Animal feed and aquaculture industries
• Cosmetic and personal care manufacturers

Its international clientele spans across North America, Europe, Southeast Asia, and Oceania, with increasing penetration into developing markets.

Capabilities

• 4 manufacturing sites including advanced fermentation and purification plants
• Over 130 granted patents, with more in the pipeline
• Dedicated R&D center employing more than 100 researchers
• Flexible production capacity for both bulk and custom nutritional solutions

Certifications and Compliance

CABIO has achieved comprehensive regulatory certifications including:

• ISO 9001
• ISO 22000
• GMP (Good Manufacturing Practice)
• HACCP
• Halal and Kosher Certifications
• GRAS status (US FDA) for key ingredients like ARA and DHA

These certifications affirm CABIO’s compliance with global food safety and quality standards, making it a preferred supplier to multinational FMCG and pharmaceutical companies.

Customer Testimonials

“CABIO is one of the few ARA suppliers globally that consistently delivers both quality and traceability. Their production system is robust, and we trust their R&D support.”
— Procurement Manager, Global Infant Formula Brand (source: LinkedIn testimonial, 2022)

“We’ve been sourcing DHA from CABIO for our North American clients, and the performance, purity, and support we receive are top-class.”
— Managing Director, Nutraceutical Distributor, USA (source: B2B client forum, 2023)

Major Achievements

• First Chinese company to achieve large-scale industrial production of ARA through microbial fermentation
• Recognized as a National High-Tech Enterprise by the Chinese government
• Listed on the STAR Market, highlighting its innovation leadership
• Partnered with over 200 global companies, including several Fortune 500 brands
• Exported products to 40+ countries as of 2023

CABIO Biotech stands at the forefront of nutritional biotechnology with its innovation-driven model, global reach, and firm commitment to quality and sustainability. Its continued focus on fermentation-based health solutions positions it as a trusted global partner in the health and nutrition value chain.